scispace - formally typeset
S

Senthamaraikannan Kabilan

Researcher at Annamalai University

Publications -  145
Citations -  2025

Senthamaraikannan Kabilan is an academic researcher from Annamalai University. The author has contributed to research in topics: Antibacterial activity & Antimicrobial. The author has an hindex of 22, co-authored 141 publications receiving 1624 citations. Previous affiliations of Senthamaraikannan Kabilan include Instituto Superior de Engenharia de Lisboa.

Papers
More filters
Journal ArticleDOI

Synthesis and in vitro microbiological evaluation of imidazo(4,5-b)pyridinylethoxypiperidones.

TL;DR: Structural-activity relationship led to the conclusion that compound 39 exerted strong in vitro antibacterial activity against Bacillus subtilis and Staphylococcus aureus whereas compounds 38 and 39 displayed promising antifungal activity against Aspergillus flavus.
Journal ArticleDOI

Synthesis, stereochemistry, and antimicrobial evaluation of substituted piperidin-4-one oxime ethers.

TL;DR: The present results may be used as key steps for the construction of novel chemical entities with better pharmacological profiles than standard drugs.
Journal ArticleDOI

Synthesis and spectral characterization of a new class of N-(N-methylpiperazinoacetyl)-2,6-diarylpiperidin-4-ones: antimicrobial, analgesic and antipyretic studies.

TL;DR: Biological studies proved that compounds 17c/18c against bacterial and 18c/20c against fungal strains exhibited promising antimicrobial activities whereas 17c or 19c/19c showed beneficial analgesic and antipyretic profiles, respectively, at a concentration of 60mg/kg and were also found to be more potent than the reference drug.
Journal ArticleDOI

Recent development of targeted approaches for the treatment of breast cancer.

TL;DR: Advances in understanding tumor biology, particularly signaling pathways, Hedgehog/Gli 1 signaling pathway, and inhibitors are considered to be important for bone metastasis and may provide vital information for the design and development of new strategies for efficacy, reduction of the side effects, and treatment strategies.
Journal ArticleDOI

Design, synthesis and biological evaluation of novel 2-[(2,4-diaryl-3-azabicyclo[3.3.1]nonan-9-ylidene)hydrazono]-1,3-thiazolidin-4-ones as a new class of antimicrobial agents.

TL;DR: These studies proved that compounds 11/18/20/23 against Staphylococcus aureus, 19/ 20/24 against Salmonella typhi show maximum inhibition potency at low concentration whereas 18/19 against Candida albicans and 19/20-21 against Rhizopus sp.